Vaccine News and Research RSS Feed - Vaccine News and Research

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
Study provides insights into climate, social factors that trigger dengue outbreaks

Study provides insights into climate, social factors that trigger dengue outbreaks

Researchers at Upstate Medical University, in collaboration with a team of international investigators studying dengue fever, have discovered new information on climate drivers of the disease and social risk factors that may be contributing to its spread, according to two scientific papers recently published in BMC Infectious Disease and BMC Public Health, open access, peer-reviewed online journals. [More]
RSV infection rate on the rise among young children

RSV infection rate on the rise among young children

Children with Respiratory Syncytial Virus (RSV), a common virus that infects the lungs and breathing passageways, has been on the rise across the nation for the last several years. Though it may only produce minor cold symptoms in adults, it can lead to serious illness in young children and those with compromised immune systems. [More]
New report examines global issues affecting vaccine confidence since the new millennium

New report examines global issues affecting vaccine confidence since the new millennium

A decade on from the Northern Nigeria polio vaccination boycott and its global costs to the polio eradication initiative, a new report examines global issues affecting vaccine confidence and hesitation since the new millennium. [More]
Two experimental Ebola vaccines appear to be safe in PREVAIL clinical trial in Liberia

Two experimental Ebola vaccines appear to be safe in PREVAIL clinical trial in Liberia

Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review. [More]
Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

Personalized medicine is getting closer to reality for women with late-stage ovarian cancer. An experimental immunotherapy is in the works that can target an individual woman's tumor and extend the time period between initial treatment and the cancer's return. [More]
Promising clinical trial results for ebola vaccines

Promising clinical trial results for ebola vaccines

Interim findings from a clinical trial (PREVAIL) in which two experimental Ebola vaccines were given to more than 600 people in Liberia indicate that the vaccines are safe for use in humans. Based on these positive results, the vaccines may continue into the next stage of clinical evaluation; a phase 3 trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. [More]
New Ebola vaccine shows promise in first phase 1 clinical trial

New Ebola vaccine shows promise in first phase 1 clinical trial

Results from the first phase 1 trial of an Ebola vaccine based on the current (2014) strain of the virus are today published in The Lancet. Until now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. The results suggest that the new vaccine is safe, and provokes an immune response in recipients, although further long-term testing will be needed to establish whether it can protect against the Ebola virus. [More]
Guinean Government initiates first efficacy trial of Ebola vaccine in Basse-Guinée

Guinean Government initiates first efficacy trial of Ebola vaccine in Basse-Guinée

The Guinean Government with the World Health Organization initiated the very first efficacy trial of an Ebola vaccine this week in an affected community of the Basse-Guinée, one of the areas where most Ebola cases are found in the country. [More]
New report explores global issues affecting confidence, hesitation about polio vaccines

New report explores global issues affecting confidence, hesitation about polio vaccines

A decade on from the Northern Nigeria polio vaccination boycott and its global costs to the polio eradication initiative, a new report examines global issues affecting confidence and hesitation about vaccines since the new millennium. [More]
Wyatt Technology’s CG-MALS system enables characterization of complex protein-protein interactions

Wyatt Technology’s CG-MALS system enables characterization of complex protein-protein interactions

Study published in Nature outlines use of Wyatt’s Calypso II system to confirm the stoichiometry of αSNAP-SNARE complex [More]
Study: HBV exposure increases immune system maturation of infants

Study: HBV exposure increases immune system maturation of infants

A Singapore led study has shown that Hepatitis B Virus Infection (HBV) exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life. These findings radically modify the way that HBV vertical infection of neonates (mother-to-child) is portrayed, and present a paradigm shift in the approach to treatment of patients with chronic hepatitis B. [More]
Immunotherapy reverses memory problems in animal model of Alzheimer's disease

Immunotherapy reverses memory problems in animal model of Alzheimer's disease

A new study from the University of Texas Medical Branch at Galveston has revealed that a single dose of an immunotherapy reverses memory problems in an animal model of Alzheimer's disease. The article appears in the March 25 issue of the Journal of Neuroscience. [More]
Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Induced pluripotent stem cells (iPSCs) -- adult cells reprogrammed back to an embryonic stem cell-like state--may better model the genetic contributions to each patient's particular disease. In a process called cellular reprogramming, researchers at Icahn School of Medicine at Mount Sinai have taken mature blood cells from patients with myelodysplastic syndrome (MDS) and reprogrammed them back into iPSCs to study the genetic origins of this rare blood cancer. [More]
Accelovance named finalist for Best Contract Research Organization at ViE Awards

Accelovance named finalist for Best Contract Research Organization at ViE Awards

Accelovance, a therapeutically focused contract research organization (CRO), has been named a finalist for "Best Contract Research Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards hosted by the World Vaccine Congress. [More]
FDA approves Quadracel vaccine to protect young children from life-threatening diseases

FDA approves Quadracel vaccine to protect young children from life-threatening diseases

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration has approved use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age. [More]
CMV-based vaccine provides long-lasting protective immunity against Ebola virus

CMV-based vaccine provides long-lasting protective immunity against Ebola virus

A cytomegalovirus (CMV)-based vaccine provides long-lasting protective immunity against Ebola virus, and has potential for development as a disseminating vaccine strategy to prevent ebolavirus infection of wild African ape populations. [More]
Norovirus vaccine may be available in the future

Norovirus vaccine may be available in the future

A multivalent candidate vaccine elicits broad antibody responses to a range of norovirus strains, including strains not included in the vaccine or previously encountered by participants, according to a new study published this week in PLOS Medicine. [More]
BIO KOREA celebrates 10th anniversary to share new information and technology in health industry

BIO KOREA celebrates 10th anniversary to share new information and technology in health industry

BIO KOREA is celebrating its 10th anniversary as a convention to share the latest information and technology in the health industry and to establish corporate partnerships among global experts. [More]

The fight continues to end tuberculosis

Today is World TB Day. The Centenary Institute is one of the leading medical research institutes in Australia championing the fight to put an end to this insidious disease. [More]
Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. [More]
Advertisement
Advertisement